Meeting Announcement – LOTRONEX

Posted by on June 5, 2013


July 10, 2013 8:00 a.m. to 5:00 p.m.: Meeting of the Drug Safety and Risk Management Advisory Committee Meeting Announcement

Where: FDA White Oak Campus
            Building 31           
            The Great Room (Rm. 1503)
            White Oak Conference Center
            10903 New Hampshire Avenue
            Silver Spring, Maryland

The Food and Drug Administration Amendments Act of 2007 requires FDA to bring, at least annually, one or more drugs with Risk Evaluation and Mitigation Strategies (REMS) with elements to assure safe use (ETASU) before its Drug Safety and Risk Management Advisory Committee (DSaRM). On July 10, 2013, the Agency plans to discuss the risk management of Lotronex (alosetron hydrochloride) tablets, Prometheus Laboratories Inc., which is approved for the treatment of women with severe diarrhea predominant irritable bowel syndrome (IBS-d). The Agency will seek the committee’s comments as to whether the REMS with ETASU for this drug assures safe use, is not unduly burdensome to patient access to the drug, and to the extent practicable, minimizes the burden to the health care delivery system.

Please click HERE for the current roster of the Drug Safety and Risk Management Advisory Committee.


ISS has over a decade of experience in developing regulatory strategies including support for FDA Advisory Committee meetings. We are involved in more FDA AdComms per year than even the largest pharmaceutical companies. For more information on how ISS can help you prepare for your next meeting, contact